Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Kidney cancer

Bap1 and Pbrm1 determine tumour grade

Nature Reviews Urology volume 14, page 391 (2017)Cite this article

Subjects

Many clear cell renal cell carcinomas (ccRCC) harbour ubiquitin carboxyl-terminal hydrolase BAP1 (BAP1) and protein polybromo-1 (PBRM1) mutations. Now, data from genetically modified mouse models indicate that conditional Bap1 or Pbrm1 knockout with Von Hippel–Lindau codeletion results in ccRCC of different grades: Bap1-deficient tumours had a higher grade with greater serine/threonine-protein kinase mTOR activation, relative to Pbrm1-deficient tumours, which had a longer latency.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Gu, Y.-F. et al. Modeling renal cell carcinoma in mice: Bap1 and Pbrm1 inactivation drive tumor grade. Cancer Discov. http://dx.doi.org/10.1158/2159-8290.CD-17-0292 (2017)

Download references

Authors
  1. Peter Sidaway
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sidaway, P. Bap1 and Pbrm1 determine tumour grade. Nat Rev Urol 14, 391 (2017). https://doi.org/10.1038/nrurol.2017.84

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrurol.2017.84

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer